

Mechanisms of transiently impaired renal function during liver transplantation

Submission date 21/06/2008	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 12/09/2008	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 12/09/2008	Condition category Urological and Genital Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Eduardo Schiffer

Contact details
Hopitaux Universitaires de Geneve
24 Micheli-du-Crest
Geneva
Switzerland
1211

Additional identifiers

Protocol serial number
CER 03-159; SHR 369-08

Study information

Scientific Title
Renal function during the perioperative period of liver transplantation

Study objectives
Hyperreninism is the major mediator of transient and acute anuria during the anhepatic phase of liver transplantation.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Committee of the Geneva University Hospitals (Commission central d'éthique de la recherche sur l'être humain des HUG). Date of approval: 24/01/2004 (ref: CER 03-159)

Study design

Observational, prospective, cross-sectional study

Primary study design

Observational

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Liver transplantation

Interventions

Observational study: Blood sampling for biologic assessment of renal function at the time of inclusion in the waiting list, at the time of anaesthesia induction on the day of liver transplantation, during the anhepatic phase, 24 hours later and finally at 6 months.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Renal function: plasma renin activity, assessed in all blood samples (see Interventions).

Key secondary outcome(s)

The following were assessed in all blood samples (see Interventions):

1. Cystatin C
2. Natraemia

Completion date

01/01/2008

Eligibility

Key inclusion criteria

1. Both males and females
2. Age 17-70 years
3. Patients scheduled for liver transplantation

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

Incapacity to comprehend the study protocol

Date of first enrolment

01/08/2004

Date of final enrolment

01/01/2008

Locations**Countries of recruitment**

Switzerland

Study participating centre

Hopitaux Universitaires de Geneve

Geneva

Switzerland

1211

Sponsor information**Organisation**

Geneva University Hospitals (Hôpitaux Universitaires de Genève) (Switzerland)

ROR

<https://ror.org/01m1pv723>

Funder(s)**Funder type**

Hospital/treatment centre

Funder Name

Geneva University Hospitals (Hôpitaux Universitaires de Genève) (Switzerland)

Results and Publications**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration